Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 Failure

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the must-buy US stocks to buy right now. On April 2, Roivant Sciences Ltd. (NASDAQ:ROIV) said its subsidiary Priovant Therapeutics had started enrolling patients in a Phase 2b/3 trial of brepocitinib for lichen planopilaris (LPP). LPP is a severe inflammatory hair loss condition and brepocitinib treats that inflammation.

Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 Failure

Roivant said that the trial structure starts with a 72-patient Phase 2b segment to refine dosing and endpoints, then flows directly into a 270-patient Phase 3 without interruption. It added that the primary endpoint being targeted is an Investigator’s Global Assessment (IGA) score of 0 or 1 with a two-point reduction. This is a more defined measure than previous LPP studies, the company noted.

Priovant CEO Ben Zimmer said brepocitinib’s mechanism is well-suited for LPP. This is because the disease is driven by TH1-polarized T-cell activity, which is the exact biology the drug is designed to suppress.

Separately, Roivant’s Immunovant unit reported that batoclimab failed to meet the primary endpoint in two Phase 3 studies testing the drug in thyroid eye disease (TED). TED is a condition where the immune system attacks the tissue behind the eyes, causing them to bulge outward. Unfortunately, the drug didn’t reduce eye bulging enough to meet the study’s goal. Immunovant is now reconsidering its future development, Roivant said.

Roivant Sciences Ltd. (NASDAQ:ROIV) develops and commercializes medicines through a network of subsidiary companies. It acquires or in-licenses drug candidates and advances them through clinical development across multiple therapeutic areas, including immunology, dermatology, and rare diseases.

While we acknowledge the risk and potential of ROIV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ROIV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 9 Best Healthcare Penny Stocks to Buy According to Hedge Funds and 7 Penny Stocks That Aren’t Scams: Best Cheap Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.